Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Moleculin Biotech Inc MBRX

Healthcare Biotechnology
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066... see more

Current News (NDAQ:MBRX)

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

GlobeNewswire 4 days ago

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

GlobeNewswire February 19, 2026

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

GlobeNewswire February 18, 2026

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

GlobeNewswire February 17, 2026

Moleculin Launches CEO Corner Platform to Share Strategic Insights

GlobeNewswire February 13, 2026

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

GlobeNewswire February 5, 2026

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects 

GlobeNewswire January 13, 2026

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

GlobeNewswire January 12, 2026

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

GlobeNewswire December 17, 2025
View More News ››

Opinion & Analysis (NDAQ:MBRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MBRX)

MBRX....Warrants exercised = more dilution post RS....Meh !

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds 2025-12-10 05:30 ET - News Release HOUSTON, Dec. 10, 2025 ...
Iseneschal - December 10, 2025

RE:MBRX....NR post RS RS 25:1 2.1 mil o/s $6.70 Eff 12/01/25

On watch sub $7
Iseneschal - December 9, 2025

MBRX....NR post RS RS 25:1 2.1 mil o/s $6.70 Eff 12/01/25

Recent Bulletins News ReleasesIn The NewsOther Date PT Symbol Type...
Iseneschal - December 9, 2025

MBRX....Meh....no more pump for this "pile"

The MM's have finished shorting the whole financing to John Q Public
Iseneschal - October 30, 2025

RE:MBRX....NR this a.m...Fluff

Make note: I'm not saying this is dead in the water because in order for them to do a P.O they have to churn it to earn it to burn...
Iseneschal - October 30, 2025

MBRX....NR this a.m...Fluff

All volume and no price Action Pumping to do a P.O Bearish at $0.55
Iseneschal - October 30, 2025
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »

Podcasts